55% of the respondents say that their companies were carrying out work related to COVID-19.
This portion includes 82% of respondents working in CROs, 56% of those working in academic institutions and 100% of those working in regulatory agencies.
Almost all the respondents whose work with antibodies related to COVID-19 say that they are working with mAbs.
However, a small proportion also say they were working with other modalities such as bispecifics.
Nearly all the respondents whose work with antibodies related to COVID-19 say that they are working on COVID-related therapeutics.
Just under a fifth of respondents said that they are working on vaccines related to COVID-19, 71% of whom are from academic institutions.
There are a diverse range of answers to this question. The most common themes for our respondents’ struggles are financial challenges, working with limited resources and the complexity of SARS-Cov-2 and COVID-19.
Regeneron is the highest named by respondents as an industry leader for COVID-19 applications.
In close second place is Eli Lilly, and both AstraZeneca and Pfizer are the third-highest suggested, in equal measures.
